Detection of EGFR Mutations in the Plasma of Patients with Lung Adenocarcinoma for Real-Time Monitoring of Therapeutic Response to Tyrosine Kinase Inhibitors?

Detection of EGFR Mutations in the Plasma of Patients with Lung Adenocarcinoma for Real-Time Monitoring of Therapeutic Response to Tyrosine Kinase Inhibitors?

Bibliographic Details
Main Authors:	Marcq, Marie, Vallée, Audrey, Bizieux, Acya, Denis, Marc G.
Format:	Online
Language:	English
Published:	Lippincott Williams & Wilkins 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132039/

Similar Items

Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients
by: Riediger, Anja Lisa, et al.
Published: (2016)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
by: Huang, Lihua, et al.
Published: (2015)

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
by: Wu, Shang-Gin, et al.
Published: (2016)

Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma
by: Tseng, Jeng-Sen, et al.
Published: (2014)

Mean platelet volume and lymphocyte-to-monocyte ratio are associated with shorter progression-free survival in EGFR-mutant lung adenocarcinoma treated by EGFR tyrosine kinase inhibitor.
by: Kousuke Watanabe, et al.

A case of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with MET amplification and epithelial-to-mesenchymal transition
by: Miyoshi, Seigo, et al.
Published: (2015)

BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations
by: Costa, Daniel B, et al.
Published: (2007)

Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells
by: Tabara, Keisuke, et al.
Published: (2012)

Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinib
by: He, Peng, et al.
Published: (2013)

Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
by: Choi, Yun Jung, et al.
Published: (2013)

Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR‐tyrosine kinase inhibitor treatment response
by: Park, Ha Young, et al.
Published: (2016)

Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor
by: Wang, Wenxian, et al.
Published: (2016)

Cathepsin S attenuates endosomal EGFR signalling: A mechanical rationale for the combination of cathepsin S and EGFR tyrosine kinase inhibitors
by: Huang, Chien-Chang, et al.
Published: (2016)

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
by: Wang, Jun, et al.
Published: (2016)

Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas
by: Gong, Yixuan, et al.
Published: (2007)

Tyrosine Kinase Inhibitors and Interferon
by: Dimou, Maria, et al.
Published: (2014)

Tyrosine Kinase Inhibitors and Pregnancy
by: Abruzzese, Elisabetta, et al.
Published: (2014)

Tyrosine Kinase Inhibitors for the Elderly
by: Hohenforst-Schmidt, Wolfgang, et al.
Published: (2016)

Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma
by: Verma, Akash, et al.
Published: (2016)

A case of Trousseau syndrome caused by pulmonary adenocarcinoma that was controlled for one year and 10 months with thrombosis treatment using an EGFR tyrosine kinase inhibitor and chemotherapy
by: Masubuchi, Hiroaki, et al.
Published: (2015)

Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR
by: Yang, Hua, et al.
Published: (2016)

The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition
by: Wu, Shang-Gin, et al.
Published: (2016)

Latest progress in tyrosine kinase inhibitors
by: Pospelova, Tatiana V., et al.
Published: (2014)

EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors
by: Chenguang Li, et al.
Published: (2018-08-01)

First‐line epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor alone or with whole‐brain radiotherapy for brain metastases in patients with EGFR‐mutated lung adenocarcinoma
by: Chen, Yongshun, et al.
Published: (2016)

MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma
by: Chiu, Chao-Hua, et al.
Published: (2015)

Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study
by: Lee, Ji Hyun, et al.
Published: (2016)

In Vitro Activation and Inhibition of Recombinant EGFR Tyrosine Kinase Expressed in Escherichia coli
by: Elloumi-Mseddi, Jihene, et al.
Published: (2013)

Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain
by: Park, Jin H., et al.
Published: (2012)

High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR
by: Wang, Fang, et al.
Published: (2013)

Predictive Efficacy of Low Burden EGFR Mutation Detected by Next-Generation Sequencing on Response to EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Carcinoma
by: Kim, Hye Sook, et al.
Published: (2013)

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation
by: Miyanaga, Akihiko, et al.
Published: (2013)

Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence
by: Wang, Xiaochun, et al.
Published: (2016)

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer
by: Hirano, Toshiyuki, et al.
Published: (2015)

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report
by: Brzezniak, Christina, et al.
Published: (2016)

Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis
by: Lu, Yunyun, et al.
Published: (2016)

Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis
by: Wang, Huan, et al.
Published: (2014)

The Relative Expression of Mig6 and EGFR Is Associated with Resistance to EGFR Kinase Inhibitors
by: Chang, Xiaofei, et al.
Published: (2013)

Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors
by: Morgillo, Floriana, et al.
Published: (2011)

EGFR Tyrosine Kinase Inhibitors Activate Autophagy as a Cytoprotective Response in Human Lung Cancer Cells
by: Han, Weidong, et al.
Published: (2011)